Revance Therapeutics Statistics
Total Valuation
CBL has a market cap or net worth of $929.08 million. The enterprise value is $2.97 billion.
Important Dates
The last earnings date was Wednesday, August 6, 2025, before market open.
| Earnings Date | Aug 6, 2025 |
| Ex-Dividend Date | Sep 15, 2025 |
Share Statistics
CBL has 30.94 million shares outstanding. The number of shares has decreased by -2.15% in one year.
| Current Share Class | 30.93M |
| Shares Outstanding | 30.94M |
| Shares Change (YoY) | -2.15% |
| Shares Change (QoQ) | +0.11% |
| Owned by Insiders (%) | 11.90% |
| Owned by Institutions (%) | 50.51% |
| Float | 18.68M |
Valuation Ratios
The trailing PE ratio is 14.15.
| Price/FFO Ratio | 4.76 |
| Price/AFFO Ratio | n/a |
| PE Ratio | 14.15 |
| Forward PE | n/a |
| PS Ratio | 1.67 |
| Forward PS | n/a |
| PB Ratio | 3.17 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 4.47 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 46.16 |
| EV / Sales | 5.50 |
| EV / EBITDA | 10.09 |
| EV / EBIT | 22.99 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.27, with a Debt / Equity ratio of 7.71.
| Current Ratio | 0.27 |
| Quick Ratio | 0.14 |
| Debt / Equity | 7.71 |
| Debt / EBITDA | 7.28 |
| Debt / FCF | n/a |
| Interest Coverage | 0.79 |
Financial Efficiency
Return on equity (ROE) is 22.15% and return on invested capital (ROIC) is 3.53%.
| Return on Equity (ROE) | 22.15% |
| Return on Assets (ROA) | 3.28% |
| Return on Invested Capital (ROIC) | 3.53% |
| Return on Capital Employed (ROCE) | 8.07% |
| Revenue Per Employee | $1.13M |
| Profits Per Employee | $134,734 |
| Employee Count | 477 |
| Asset Turnover | 0.22 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CBL has paid $461,000 in taxes.
| Income Tax | 461,000 |
| Effective Tax Rate | 0.72% |
Stock Price Statistics
The stock price has increased by +17.07% in the last 52 weeks. The beta is 1.55, so CBL's price volatility has been higher than the market average.
| Beta (5Y) | 1.55 |
| 52-Week Price Change | +17.07% |
| 50-Day Moving Average | 26.40 |
| 200-Day Moving Average | 27.50 |
| Relative Strength Index (RSI) | 76.31 |
| Average Volume (20 Days) | 131,582 |
Short Selling Information
The latest short interest is 1.18 million, so 3.81% of the outstanding shares have been sold short.
| Short Interest | 1.18M |
| Short Previous Month | 1.15M |
| Short % of Shares Out | 3.81% |
| Short % of Float | 6.30% |
| Short Ratio (days to cover) | 9.26 |
Income Statement
In the last 12 months, CBL had revenue of $539.45 million and earned $64.27 million in profits. Earnings per share was $2.10.
| Revenue | 539.45M |
| Gross Profit | 346.23M |
| Operating Income | 129.06M |
| Pretax Income | 31.14M |
| Net Income | 64.27M |
| EBITDA | 294.05M |
| EBIT | 129.06M |
| Earnings Per Share (EPS) | $2.10 |
Full Income StatementBalance Sheet
The company has $100.33 million in cash and $2.14 billion in debt, giving a net cash position of -$2.04 billion or -$65.92 per share.
| Cash & Cash Equivalents | 100.33M |
| Total Debt | 2.14B |
| Net Cash | -2.04B |
| Net Cash Per Share | -$65.92 |
| Equity (Book Value) | 277.51M |
| Book Value Per Share | 9.35 |
| Working Capital | -728.74M |
Full Balance SheetCash Flow
| Operating Cash Flow | 207.21M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
Gross margin is 64.18%, with operating and profit margins of 23.92% and 12.18%.
| Gross Margin | 64.18% |
| Operating Margin | 23.92% |
| Pretax Margin | 11.92% |
| Profit Margin | 12.18% |
| EBITDA Margin | 54.51% |
| EBIT Margin | 23.92% |
| FCF Margin | n/a |
